Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction–associated steatotic liver disease

Abstract

Lower noninvasive test cut-points may be needed to optimize surveillance for significant fibrosis due to metabolic dysfunction-associated steatotic liver disease in Hispanic populations commensurate with their higher burden and severity of disease.